Figure 2.

Retrieval of tissue‐reported mutations in plasma in comparison to cell‐free DNA (cfDNA) concentration and the detection of circulating tumor cells (CTCs). Corresponding to higher cfDNA levels, total Droplet Digital PCR detection events in the wild‐type and mutation channel increased, which, however, did not correlate with successful retrieval of tissue‐reported variants in plasma. CTCs were detected in blood samples from patients of all cancer stages, highlighting that the analysis of tumor‐derived cells in the periphery will possibly complement the limited information received by cfDNA analysis. ^†The CRC‐derived KRAS mutation (G12C) was not verified in plasma from patient 374‐CB‐M; however, the G12D variant originating from the synchronous stage IV cancer of the pancreas was detected